• Solutions For...
  PK/PD Modeling Pharmacokinetics R&D Management Clinical Medicine Biostatistics Clinical Pharmacology Data Management Formulation Development Marketing Toxicology Regulatory Affairs
• Products
  Analysis Phoenix WinNonlin Phoenix NLME WinNonlin AutoPilot IVIVC Toolkit Trial Simulator Data Management Pharsight Knowledgebase Server PKS Online Phoenix Connect Reporting PKS Reporter Drug Model Explorer Validation Phoenix Validation Suite PKS Validation Suite
• Services
  Strategic Consulting Services Reporting and Analysis Services
• Training
  Software Product Training Upcoming Courses and Workshops Applied Modeling and Simulation Training Curriculum
• Support
  Customer Support Portal
• Reference Library
  Articles and Publications Books Case Studies Presentations/Posters/Abstracts Event Archive Executive Issue Briefs Newsletters Product Data Sheets Product Videos White Papers
• Events
  Calendar of Events Upcoming Events Conference Presentations, Posters & Abstracts Recent Contributions Events Center Online Events Schedule Archive Training Upcoming Courses & Workshops
• About Pharsight
  Management Team Customers Academic Users FDA-Pharsight CRADA Partners Press Releases Pharsight In the News Calendar of Events Careers Contact Us

Product Detail

• Phoenix NLME Home
• Features
• Benefits
• Requirements

Product Resources

• Discussion Forum
• Tips & Tricks
• Webinars
• FAQ ®
• Data Sheet 
• Upgrade Now or Order

Related Products & Services

• Phoenix Connect
• Phoenix WinNonlin
• Phoenix Validation Suite
• PKS
• Training
• Reporting & Analysis Services

Phoenix WNL has value for...

• Toxicology
• Pharmacokinetics
• PK/PD Modeling
• Clinical Pharmacology
• Formulation Development

Phoenix NLME™ ? Get It Now!

If you are currently a licensed user of WinNonMix® and have a current support agreement in place with Pharsight, then upgrading to Phoenix NLME is free. Phoenix NLME will use your existing WinNonMix license to operate. 

Phoenix NLME has been designed with parallelized model estimation engines to take advantage of significant speed gains available on modern computers running multiple processors.  Multi-core CPUs are now the norm. We believe these changes are real and permanent, and that they will significantly improve population-based modeling in drug development by enabling scientists to increase the complexity and quantity of their analyses.

For this reason, Pharsight is introducing a new licensing model that better conforms to the advances in computing technology and that will enable us to continue to stay on the cutting edge of software development for PK/PD scientists. All commercial WinNonMix customers will be receiving an email from Pharsight with more information on this new licensing structure, as well as detailed instructions to get up and running with Phoenix NLME.

If you have not heard from us in regard to your upgrade path from WinNonMix to Phoenix NLME, please email licensing@pharsight.com.

If you do not have a valid WinNonMix license, contact Sales at sales@pharsight.com.